(A Top Pick Dec 19/16. Down 7%.) People are afraid Amazon is going to come in and take their space. That is unlikely to happen. They have 10,000 locations in the US along with 1600 in Target stores and 1200 in mini-clinics. A wonderful platform to capture the patient experience, which is exactly what they are trying to do.

(A Top Pick Dec 19/16. Up 9%.) He likes the US financials, but has moved away from this in favour of Morgan Stanley (MS-N). Didn't feel it was executing as well as it should have been. Trading volumes have been low, and he wanted to move more towards the retail opportunity in addition to capital markets.

Trades at a relatively good valuation, about 15X operating. Also, this is more of an e-commerce play. Volumes are rising and the cost structure is changing dramatically in their favour. A great hold just from an operating standpoint, but there is also a catalyst for higher growth rates into the future, because of cost containment.

Has always shied away from this. They had a very successful ramp with their HEP C drug portfolio, a peak, followed by a fairly rapid decline. The decline came on a couple of issues. It was a total cure so there wasn't a recurring customer. Also, a number of other pharmacies came out with products that competed effectively, so there was price competition. The HEP C portfolio is falling about 40% year-over-year.

This company has responded very well to the Amazon threat. They acquired jet.com, an online retailer, and they are taking on Amazon. A retailer, but it’s also a grocer in that more than 50% of revenues come from groceries, very, very low margin commodities.

He would be a little cautious. It was amongst the 1st wave of technology stocks. They dominated in the hardware of switches and routers. They’re trying to reinvent themselves, but as a big ship, it is going to be very tough to turn. The fundamentals have been relatively flat in terms of revenue growth and earnings growth. The company has gotten on the valuation escalator i.e., as people become more positive about the company, they bid it up to the point where the valuation rises, with a higher P, but with a similar E. That can only go on so long.

This has done extremely well on the price side, but its valuations have become less and less expensive, which means the fundamentals are growing at a faster pace than the price. Last quarter, they reported a year-over-year revenue growth of 24%.